Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Calcium Channel Blocker Market Growth in 2025?

The market for calcium channel blockers has seen robust growth in the past few years. It is projected to expand from $15.56 billion in 2024 to $16.62 billion in 2025, with a CAGR of 6.8%. Factors contributing to growth during the historical period include a rise in cardiovascular diseases, an aging population, progress in medical research, lifestyle changes, and heightened awareness.

What Is the Forecast for the Calcium Channel Blocker Market Size Through 2029?

In the ensuing years, a robust surge is forecasted in the calcium channel blocker market, anticipated to achieve a valuation of $22.07 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 7.4%. This growth can be ascribed to an increasing global incidence of cardiovascular diseases, advancements in personalized medicine, augmented accessibility to healthcare, broadening of indications, regulatory approvals, and market expansion. Key trends in the future include market growth, technological innovations, regulatory environment, competitive evaluation, patient preferences, and increased awareness.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

What are the Key Market Players in Calcium Channel Blocker Market and How They’re Evolving?

Major companies operating in the calcium channel blocker market include Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Cadila Healthcare Limited, Covis Pharma BV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A., Clearsynth Labs Ltd., Searle LLC, Bayer AG, AstraZeneca plc, Wyeth-Ayerst Lederle Inc., GlaxoSmithKline Plc., AbbVie Inc., Silvergate Pharmaceuticals Inc., Exela Pharma Sciences LLC, Arbor Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd.

What Are the Primary Growth Drivers in the Calcium Channel Blocker Market?

The rising incidence of cardiovascular diseases is anticipated to propel the growth of the calcium channel blocker market. Cardiovascular disease, a condition affecting the heart or blood vessels, oftentimes necessitates the use of calcium channel blockers (CCBs) to decrease the risk of heart failure and stroke. Thus, the escalating incidence of cardiovascular diseases is expected to surge the demand for these blockers. To illustrate, a report from the American College of Cardiology, a non-profit medical association based in the U.S., stated in August 2022 that it is predicted all four cardiovascular risk factors will rise between 2025 and 2060 within the U.S. Diabetes will see the most significant percentage increase, escalating by 39.3% to 55 million individuals. This is followed by dyslipidemia with an increase of 27.6% to 126 million, hypertension with an increase of 25.1% to 162 million, and obesity with an increase of 18.3% to 126 million. The most considerable predicted increases in rates of cardiovascular diseases were found in stroke (33.8% to 15 million) and heart failure (33.4% to 13 million), then ischemic heart disease (30.7% to 29 million) and heart attack (16.9% to 16 million). Consequently, the rising incidence of cardiovascular diseases is the driving force behind the progress of the calcium channel blocker market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9428&type=smp

What Are the Leading Segments in the Global Calcium Channel Blocker Industry?

The calcium channel blocker market covered in this report is segmented –

1) By Drug Class: Dihydropyridine, Benzothiazepine, Phenylalkylamine, Other Drug Classes

2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias

3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Dihydropyridine: Amlodipine, Nifedipine, Felodipine, Nicardipine, Isradipine

2) By Benzodiazepine: Diazepam

3) By Phenylalkylamine: Verapamil

4) By Other Drug Classes: Bepridil, Lercanidipine, Cilnidipine

What Are the Key Market Trends in the Calcium Channel Blocker Industry?

The calcium channel blocker market is experiencing a surge in popularity for product innovation. Major market players are strategically focusing on creating novel products to maintain their competitive edge. An instance worth noting is the June 2022 introduction of Norliqva by CMP Pharma, a pharmaceutical manufacturer based in the US. This product, a besylate salt of amlodipine, is the first and exclusive oral liquid solution of a long-acting calcium channel blocker. What sets Norliqva apart is its usage as an amlodipine liquid remedy for treating high blood pressure in individuals over the age of six. Norliqva offers a solution to the complexities and inconsistencies associated with crushing or synthesizing amlodipine tablets, ensuring consistent dosage and bioequivalence. It is particularly intended for a segment of patients who need amlodipine but struggle with swallowing or cannot swallow at all.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

What Is the Regional Outlook for the Calcium Channel Blocker Market?

North America was the largest region in the calcium channel blocker market in 2024. The regions covered in the calcium channel blocker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9428

This Report Delivers Insight On:

1. How big is the calcium channel blocker market, and how is it changing globally?

2. Who are the major companies in the calcium channel blocker market, and how are they performing?

3. What are the key opportunities and risks in the calcium channel blocker market right now?

4. Which products or customer segments are growing the most in the calcium channel blocker market?

5. What factors are helping or slowing down the growth of the calcium channel blocker market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model